Prime Medicine, Inc. (PRME) Income Statement
PRME 2025 at a glance
Fiscal year ended December 31, 2025 · U.S. dollarsPRME revenue and net income
Where PRME's revenue goes
2025Each bar shows an amount and its share of revenue. PRME kept −4,342.4% of revenue as net income.
PRME profit margins
PRME growth rates
to 2025| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Revenue | +55.3% | −3.8% | −2.3% | — |
| Gross profit | −190.1% | — | — | — |
| Operating income | — | — | — | — |
| Net income | — | — | — | — |
| EPS (diluted) | — | — | — | — |
1-year change and average annual growth (CAGR) over 3, 5 and 10 fiscal years. "—" when a starting value was zero or negative.
PRME quarterly EPS vs estimates
Prime Medicine beat the analyst EPS estimate in 3 of the last 8 quarters. Next report: November 6, 2026 (estimate $-0.23).
PRME income statement
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | |
|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $3.0M | $0 | $5.2M | $0 | $5.2M | $0 |
| Cost of revenue | $7.3M | $6.1M | $4.7M | $12.0M | $4.9M | $3.0M | $2.8M |
| Gross profit | −$2.7M | $3.0M | −$4.7M | −$12.0M | −$4.9M | $2.2M | −$2.8M |
| Research & development | $160.6M | $155.3M | $147.9M | $86.7M | $70.5M | $3.0M | $920,000 |
| Sales, general & admin | $52.3M | $50.2M | $48.0M | $29.8M | $13.9M | $3.2M | $3.8M |
| Total operating expenses | $205.7M | $205.4M | $204.8M | $116.5M | $84.5M | $3.2M | $2.2M |
| Operating income | −$208.3M | −$202.5M | −$204.8M | −$116.5M | −$84.5M | −$932,000 | −$2.2M |
| Interest income | $4.1M | $3.5M | $2.8M | — | — | — | — |
| Interest expense | — | — | — | $12.1M | $81.8M | $10.3M | — |
| Income before taxes | −$201.1M | −$195.9M | −$198.4M | −$122.8M | −$165.9M | −$1.5M | −$2.5M |
| Income taxes | — | — | −$279,000 | −$948,000 | −$486,000 | $1.9M | $4,000 |
| Net income | −$201.1M | −$195.9M | −$198.1M | −$121.8M | −$165.4M | −$3.4M | −$2.5M |
| EBITDA | −$195.8M | −$189.8M | −$186.6M | −$120.5M | −$165.3M | −$889,000 | −$2.2M |
| EPS (diluted) | −$1.37 | −$1.65 | −$2.18 | −$2.73 | −$1.73 | −$0.04 | −$0.03 |
| Gross margin | −58.1% | 100.0% | — | −230.6% | — | 42.8% | — |
| Operating margin | −4,498.1% | −6,787.4% | — | −2,236.9% | — | −17.9% | — |
| Net margin | −4,342.4% | −6,566.6% | — | −2,338.2% | — | −65.5% | — |
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Jun '25 | Mar '25 | Dec '24 | Sep '24 | Jun '24 | Mar '24 | Dec '23 | Sep '23 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $1.2M | $856,000 | $838,000 | $1.2M | $1.1M | $1.5M | $2.2M | $209,000 | $37.8M | $591,000 | $25.7M | $0 |
| Cost of revenue | $0 | $1.9M | $1.9M | $44.0M | $1.9M | $1.7M | $1.7M | $1.6M | $1.5M | $1.3M | $1.2M | $4.4M |
| Gross profit | $1.2M | −$1.0M | $838,000 | −$42.8M | −$749,000 | $1.5M | $2.2M | $209,000 | −$1.5M | −$724,000 | −$1.2M | −$4.4M |
| Research & development | $33.4M | $34.1M | $34.7M | $44.0M | $41.4M | $40.6M | $34.1M | $40.3M | $43.1M | $37.8M | $41.5M | $41.0M |
| Sales, general & admin | $11.0M | $17.4M | $14.7M | $11.2M | $13.1M | $13.3M | $12.3M | $14.1M | $12.6M | $11.2M | $14.3M | $10.5M |
| Total operating expenses | $44.4M | $49.7M | $49.4M | $11.2M | $52.6M | $53.8M | $46.4M | $54.4M | $55.7M | $47.6M | $68.0M | $51.5M |
| Operating income | −$43.3M | −$50.7M | −$48.6M | −$54.0M | −$53.4M | −$52.4M | −$44.2M | −$54.2M | −$55.7M | −$48.3M | −$68.0M | −$51.5M |
| Interest income | $788,000 | $1.0M | $1.1M | $1.1M | $743,000 | $1.2M | $1.5M | $697,000 | $611,000 | $676,000 | — | $410,000 |
| Interest expense | — | — | — | — | — | — | — | — | — | — | $434,000 | — |
| Income before taxes | −$42.1M | −$49.1M | −$46.1M | −$50.6M | −$52.6M | −$51.9M | −$42.3M | −$52.5M | −$55.5M | −$45.6M | −$65.6M | −$50.8M |
| Income taxes | — | — | — | — | — | — | — | — | −$134,000 | $134,000 | $558,000 | −$108,000 |
| Net income | −$42.1M | −$49.1M | −$46.1M | −$50.6M | −$52.6M | −$51.9M | −$42.3M | −$52.5M | −$55.3M | −$45.8M | −$65.6M | −$50.7M |
| EBITDA | −$40.3M | −$47.3M | −$44.2M | −$48.7M | −$50.7M | −$50.2M | −$40.6M | −$51.0M | −$53.9M | −$44.3M | −$53.3M | −$50.2M |
| EPS (diluted) | −$0.24 | −$0.28 | −$0.24 | −$0.32 | −$0.41 | −$0.40 | −$0.31 | −$0.44 | −$0.46 | −$0.44 | −$0.72 | −$0.55 |
| Gross margin | 100.0% | −116.8% | 100.0% | −3,491.0% | −67.2% | 100.0% | 100.0% | 100.0% | −4.1% | −122.5% | −4.9% | — |
| Operating margin | −3,750.9% | −5,917.5% | −5,800.5% | −4,406.0% | −4,787.2% | −3,603.3% | −2,025.7% | −25,948.3% | −147.4% | −8,179.5% | −264.8% | — |
| Net margin | −3,649.0% | −5,738.6% | −5,498.7% | −4,129.1% | −4,716.7% | −3,568.8% | −1,936.6% | −25,128.2% | −146.5% | −7,743.0% | −255.5% | — |
Quarterly columns are labeled by the month the quarter ended. Figures in U.S. dollars as reported in PRME's financial statements (latest annual report filed March 3, 2026); data from EODHD. Sales, general & administrative expenses include sales and marketing.
PRME financial results
In fiscal year 2025 (ended December 31, 2025), Prime Medicine reported revenue of $4.6 million, up 55.3% from the year before. It had a net loss of $201.1 million, a net profit margin of −4,342.4%. Diluted earnings per share came to −$1.37. Over five years revenue grew at an average rate of −2.3% a year.
See the PRME stock overview for the latest quote and news, or the PRME chart for price history and technical indicators.
PRME income statement FAQ
What is Prime Medicine's annual revenue?
Prime Medicine reported total revenue of $4.6 million for fiscal year 2025, which ended on December 31, 2025. That was up 55.3% from $3.0 million the previous year.
Is Prime Medicine profitable?
No. Prime Medicine reported a net loss of $201.1 million in fiscal 2025, a net profit margin of −4,342.4%; its operating margin was −4,498.1%.
What is Prime Medicine's gross margin?
Prime Medicine's gross margin was −58.1% in fiscal 2025: for every $100 of revenue, Prime Medicine kept $-58 after the direct cost of its products and services.
How much does Prime Medicine spend on research and development?
Prime Medicine spent $160.6 million on research and development in fiscal 2025, 3,468.0% of revenue.
How fast is Prime Medicine growing?
Revenue grew −2.3% a year on average over the last five fiscal years, from $5.2 million to $4.6 million.
What are Prime Medicine's earnings per share?
Prime Medicine earned $-1.37 per diluted share in fiscal 2025, compared with $-1.65 a year earlier.
When will Prime Medicine report its next earnings?
Prime Medicine is expected to report results for the quarter ending September 30, 2026 on November 6, 2026 before the market opens.
When does Prime Medicine's fiscal year end?
Prime Medicine's fiscal year ends in December. The latest annual report covers the year ended December 31, 2025 and was filed on March 3, 2026.